These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26390769)

  • 1. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.
    Van Doren BA; Foulks-Rodriguez KA; Yarborough W
    J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.
    Kanate D; Folk D; Cirone S; Gordon J; Kirlew M; Veale T; Bocking N; Rea S; Kelly L
    Can Fam Physician; 2015 Feb; 61(2):160-5. PubMed ID: 25821874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.
    Apelt SM; Scherbaum N; Gölz J; Backmund M; Soyka M
    Pharmacopsychiatry; 2013 May; 46(3):94-107. PubMed ID: 23293011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine treatment in an urban community health center: what to expect.
    Cunningham C; Giovanniello A; Sacajiu G; Whitley S; Mund P; Beil R; Sohler N
    Fam Med; 2008; 40(7):500-6. PubMed ID: 18928077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 20. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.